Stroke Diagnostic and Therapeutic Market Size is Forecasted to Hit US$ 65.45 Billion by 2030

Canada – The stroke diagnostic and therapeutic market was valued at 32.69 billion USD in 2021 and will grow with a CAGR of 8% from 2021 to 2030.

The stroke diagnostic and therapeutic market size is forecasted to reach around US$ 65.45 billion by 2030. The report contains 150+ pages with detailed analysis

Stroke is a brain attack, and when blood supply to the brain is diminished or halted, it occurs. Due to the inadequate supply of oxygen and nutrients to the brain, brain cells die in this state. It can happen to anybody at any moment and its manifestations are hemorrhagic, ischemic and ischemic transient assaults. Blockage of arteries linked to the brain is the main cause of ischemic stroke, while hemorrhagic stroke is caused by brain arteries bursting open or leaking blood. It leads to TIA stroke if blood flow is momentarily disrupted for a short amount of time. The fifth leading cause of adult disability and adult mortality in North America is stroke, according to data released by the National Stroke Association.

Stroke Diagnostic and Therapeutic Market Estimations Y-O-Y:

• Market Size Was Valued In 2021: US$ 32.69 Billion
• Market Size Is Projected to Grow By 2022: US$ 35.28 Billion
• Market Size Is Projected to Grow By 2023: US$ 38.08  Billion
• Market Size Is Projected to Grow By 2024: US$ 41.11 Billion
• Market Size Is Projected to Grow By 2025: US$ 44.4 Billion
• Market Size Is Projected to Grow By 2026: US$ 47.96 Billion
• Market Size Is Projected to Grow By 2027: US$ 51.82 Billion
• Market Size Is Projected to Grow By 2028: US$ 56 Billion
• Market Size Is Projected to Grow By 2029: US$ 60.53 Billion
• Market Size Is Projected to Grow By 2030: US$ 65.45 Billion
• Compound Annual Growth Rate (CAGR) from 2022 to 2030: 8 percent

Growth Factors:

Increasing number of patients at risk of increasing stroke across the globe is major factor driving growth of the global stroke diagnostics and therapeutic market. Increasing prevalence of high blood pressure among the population across the globe which is a key risk factor fuelling patients developing stroke at risk. For instance, according to the data published by American Heart Association in 2018, 103 million U.S. adults have high blood pressure and are increasing at major rate. Geriatric population is increasing now days in developed as well as emerging economies which are major factor of generating developing stroke at risk among individuals.

Additionally, some of the major factors increasing risk of stroke are smoking, diabetes, high cholesterol, physical inactivity and obesity, carotid or other artery disease. These factors are creating huge demand for the stroke diagnostics and therapeutic in turn which is driving growth of the global market. Increased healthcare expenditure is another factor anticipated to boost growth of the global market in the near future. Developed economies across the globe such as U.S., Canada, Germany, and U.K. are spending huge amount of money on healthcare each year. This is owing to increasing awareness among the individuals across the globe regarding better health outcomes, coupled with increasing per capita income tend to have a higher level of health expenditures per capita worldwide.

Furthermore, health deteriorates and health-care spending is increasing owing to growing old age population across the globe which is in turn tends to support growth of the global stroke diagnostics and therapeutic market. Moreover, the private and public payer spending has also increased. The United States has a healthcare system that consists primarily of private providers and private insurers, but since healthcare has become a greater part of the economy, the government has received a higher share of healthcare funding. All these factors are supporting growth of the global market in the near future.

Scope of the Stroke Diagnostic and Therapeutic Market

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The stroke diagnostic and therapeutic report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2020, North America dominated the global market with a market share of more than 30%. The growth of the North American region is owing to increased number of stroke patient in the United States and Canada of the region. Further, rapidly increasing old age population in the North American countries is becoming major factor for the growth of the target industry in the region. Europe is another important region holding significant share owing to favorable government policies, increasing geriatric population in the countries of Europe. Moreover, increasing patient awareness and increasing health care expenditure are expected to propel growth of the target industry in the countries of Asia Pacific especially in the China, Japan, and India of the region.

Key Players:

The stroke diagnostic and therapeutic market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the stroke diagnostic and therapeutic market include:

• Neural Analytics
• Cordis Corporation
• Cerebrotech Medical Systems, Inc.
• Koninklijke Philips N.V.
• Medtronic plc.
• Boston Scientific Corporation
• GE Healthcare
• Medfield Diagnostics
• Samsung Neurologica
• NIRX
• Gowerlabs
• Siemens AG
• Genentech Inc.
• Merck & Co., Inc.
• Hyperfine MRI
• Stryker Corporation
• Abbott Laboratories

Market Segmentation

By Type

• Diagnostics
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography Scan (CT scan)
  • Electrocardiography
  • Carotid Ultrasound
  • Cerebral Angiography
  • Others
• Therapeutics
  • Tissue Plasminogen Activator
  • Antiplatelet
  • Antihypertensive
  • Anticoagulant

By Application

• Haemorrhagic Stroke
• Ischemic Stroke

Regional Segmentation

• North America (U.S. and Canada)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Stroke Diagnostic And Therapeutic Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Stroke Diagnostic And Therapeutic Market

5.1. Covid-19: stroke diagnostic and therapeutic Industry Impact
5.2. stroke diagnostic and therapeutic Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and stroke diagnostic and therapeutic Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for stroke diagnostic and Therapeutic Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Stroke Diagnostic And Therapeutic Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1.1. Increasing number of patients at risk of developing stroke
6.1.1.1.2. Increasing patient awareness
6.1.1.1.3. Increased health care expenditure
6.1.2. Market Restraints
6.1.2.1. High cost of treatment and unfavorable reimbursement scenario
6.1.3. Market Opportunities
6.1.3.1. Growing ongoing research & development in the healthcare sector technologies and emerging markets

Chapter 7. Global Stroke Diagnostic And Therapeutic Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. stroke diagnostic and Therapeutic Market Revenue by Market Players (2017 – 2020)
7.1.1.2. stroke diagnostic and Therapeutic Market Revenue Market Share by Market Players (2017 – 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Stroke Diagnostic And Therapeutic Market, By Type

8.1. stroke diagnostic and Therapeutic Market, by Type, 2017-2030
8.1.1. Diagnostic
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Therapeutics
8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Stroke Diagnostic And Therapeutic Market, By Application

9.1. stroke diagnostic and therapeutic Market, by Application, 2017-2030
9.1.1. Haemorrhagic Stroke
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ischemic Stroke
9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Stroke Diagnostic And Therapeutic Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue Forecast by Type (2017-2030)
10.1.2. Market Revenue Forecast by Application(2017-2030)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2017-2030)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2017-2030)
10.2. Europe
10.2.1. Market Revenue Forecast by Type (2017-2030)
10.2.2. Market Revenue Forecast by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2017-2030)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2017-2030)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Type (2017-2030)
10.3.2. Market Revenue Forecast by Application (2017-2030)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2017-2030)
10.4. LATAM
10.4.1. Market Revenue Forecast by Type (2017-2030)
10.4.2. Market Revenue Forecast by Application (2017-2030)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2017-2030)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2017-2030)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Type (2017-2030)
10.5.2. Market Revenue Forecast by Application (2017-2030)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2017-2030)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2017-2030)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2017-2030)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2017-2030)

Chapter 11. Company Profiles

11.1. Boston Scientific Corporation
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. Product Details, Specification, Application
11.1.3. Revenue, Price, and Gross Margin (2017-2020)
11.1.4. Recent Developments and Strategies
11.2. Medtronic plc
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Application
11.2.3. Revenue, Price, and Gross Margin (2017-2020)
11.2.4. Recent Developments and Strategies
11.3. Cerebrotech Medical Systems, Inc.
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Application
11.3.3. Revenue, Price, and Gross Margin (2017-2020)
11.3.4. Recent Developments and Strategies
11.4. Cordis Corporation
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Application
11.4.3. Revenue, Price, and Gross Margin (2017-2020)
11.4.4. Recent Developments and Strategies
11.5. Neural Analytics
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Application
11.5.3. Revenue, Price, and Gross Margin (2017-2020)
11.5.4. Recent Developments and Strategies
11.6. Koninklijke Philips N.V.
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Application
11.6.3. Revenue, Price, and Gross Margin (2017-2020)
11.6.4. Recent Developments and Strategies
11.7. Medfield Diagnostics
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Application
11.7.3. Revenue, Price, and Gross Margin (2017-2020)
11.7.4. Recent Developments and Strategies
11.8. GE Healthcare
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Application
11.8.3. Revenue, Price, and Gross Margin (2017-2020)
11.8.4. Recent Developments and Strategies
11.9. Samsung Neurologica
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Application
11.9.3. Revenue, Price, and Gross Margin (2017-2020)
11.9.4. Recent Developments and Strategies
11.10. Siemens AG
11.10.1. Company Overview, Business Information, Regional Presence
11.10.2. Product Portfolio Analysis
11.10.2.1. Product Details, Specification, Application
11.10.3. Revenue, Price, and Gross Margin (2017-2020)
11.10.4. Recent Developments and Strategies
11.11. NIRX
11.11.1. Company Overview, Business Information, Regional Presence
11.11.2. Product Portfolio Analysis
11.11.2.1. Product Details, Specification, Application
11.11.3. Revenue, Price, and Gross Margin (2017-2020)
11.11.4. Recent Developments and Strategies
11.12. Gowerlabs
11.12.1. Company Overview, Business Information, Regional Presence
11.12.2. Product Portfolio Analysis
11.12.2.1. Product Details, Specification, Application
11.12.3. Revenue, Price, and Gross Margin (2017-2020)
11.12.4. Recent Developments and Strategies
11.13. Stryker Corporation
11.13.1. Company Overview, Business Information, Regional Presence
11.13.2. Product Portfolio Analysis
11.13.2.1. Product Details, Specification, Application
11.13.3. Revenue, Price, and Gross Margin (2017-2020)
11.13.4. Recent Developments and Strategies
11.14. Genentech Inc.
11.14.1. Company Overview, Business Information, Regional Presence
11.14.2. Product Portfolio Analysis
11.14.2.1. Product Details, Specification, Application
11.14.3. Revenue, Price, and Gross Margin (2017-2020)
11.14.4. Recent Developments and Strategies
11.15. Merck & Co., Inc.
11.15.1. Company Overview, Business Information, Regional Presence
11.15.2. Product Portfolio Analysis
11.15.2.1. Product Details, Specification, Application
11.15.3. Revenue, Price, and Gross Margin (2017-2020)
11.15.4. Recent Developments and Strategies
11.16. Hyperfine MRI
11.16.1. Company Overview, Business Information, Regional Presence
11.16.2. Product Portfolio Analysis
11.16.2.1. Product Details, Specification, Application
11.16.3. Revenue, Price, and Gross Margin (2017-2020)
11.16.4. Recent Developments and Strategies
11.17. Abbott Laboratories
11.17.1. Company Overview, Business Information, Regional Presence
11.17.2. Product Portfolio Analysis
11.17.2.1. Product Details, Specification, Application
11.17.3. Revenue, Price, and Gross Margin (2017-2020)
11.17.4. Recent Developments and Strategies

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333